<div><div></div><div><span><p><span>KALA BIO, Inc. reported a smaller net loss in the first quarter of 2026, recording a net loss attributable to common stockholders of $(1.6M) compared with a $(8.9M) loss in the year‑ago quarter; diluted net loss per share was $(0.14) versus $(70.49) in Q1 2025.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Net income: Net loss attributable to common stockholders of $(1.6M) for Q1 2026, improved from a net loss of $(8.9M) in Q1 2025.</span></li><li><span>Diluted EPS: Diluted net loss per share of $(0.14) for Q1 2026, versus $(70.49) in Q1 2025.</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Strategic pivot to AI platform: The company shifted from MSC-S biologics to developing and commercializing an on‑premises Researgency AI platform targeted at biotech and pharma customers.</span></li><li><span>Asset monetization focus: KALA BIO is pursuing licensing, collaborations or sales for KPI‑012, KPI‑014 and related intellectual property to preserve value from prior biologics programs.</span></li><li><span>Operational cost reduction: The company ceased KPI‑012 development and significantly reduced R&amp;D and G&amp;A headcount and expenses to align with the new AI strategy.</span></li><li><span>Partnerships and licensing milestone: Executed an exclusive license and development agreement for the Researgency Platform that includes deliverables, equity and an option to acquire the licensor.</span></li></ul><p><span>Original SEC Filing: </span>KALA BIO, Inc. [ KALA ] - 10-Q - May. 15, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

KALA

LABU

IBBQ

ARKG

SBIO

<p>KALA BIO, Inc. reported a net loss of $(1.6M) in Q1 2026, an improvement from $(8.9M) in Q1 2025, with diluted EPS at $(0.14) compared to $(70.49) a year prior. The company is pivoting to an AI platform for biotech and pharma, focusing on asset monetization and operational cost reductions, including ceasing KPI-012 development. They have also executed a licensing agreement for the Researgency Platform.</p>

TradingView

KALA BIO

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary